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A P-sheet peptide inhibitor of E47 dimerization and DNA binding 
lndraneel Ghosh and Jean Chmielewski 
Background: Many transcription factors are active only in their dimeric form, 
including the basic-helix-loop-helix (bHLH) family of transcription factors. The 
disruption of the dimer therefore presents a means of inhibiting the biological 
functions of such transcription factors. E47 is a homodimeric bHLH 
transcription factor with a four-helix bundle dimerization interface. Here, we 
investigate the concept of dimerization inhibition using peptides derived from 
the dimerization domain of E47. 
Results: We have synthesized several peptides corresponding to the E47 
dimerization interface that inhibit E47 DNA-binding activity with IC,, values in 
the range of 3.6-l 20 mM. Interestingly, helix II, a peptide corresponding to the 
carboxy-terminal helix of the E47 dimerization interface, adopted a P-sheet 
structure in solution, as shown using circular dichroism (CD), and inhibited the 
binding of E47 to DNA at equimolar concentrations. Size-exclusion 
chromatography, analytical ultracentrifugation and cross-linking experiments 
verified that this peptide prevented E47 dimerization. Furthermore, CD 
experiments provided evidence that helix II could induce a P-sheet secondary 
structure upon the highly a-helical E47 bHLH domain. 
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Conclusions: This study is the first demonstration of dissociative inhibition in 
the bHLH class of transcription factors and also provides an example of P-sheet 
induction in an a-helical protein. Future experiments will probe the structural 
determinants of the P-sheet secondary structure in helix II and investigate the 
generality of the dissociative strategy in other transcription factor families. 
Introduction 
The design of agents to inhibit transcriptional activation of 
genes is an essential component of gene-targeted therapeu- 
tic strategies. One of the major methods developed for 
interfering with transcription has been the design of agents 
to interact directly with DNA [l]. Many classes of efficient 
DNA-binding agents have been developed, including 
intercalators [Z], minor-groove binders [3,4], antisense [S] 
and triple-helix oligonucleotides [6], and carbohydrates [7]. 
Strategies designed to interfere directly with transcription 
factors have been approached with designed dominant- 
negative proteins, mimicking naturally occurring proteins 
that modulate transcription [8,9]. More recently, a new 
protein-protein dissociation based approach for regulating 
the biological functions of oligomeric proteins has been dis- 
closed [lo]. Thus, this strategy seems appropriate for appli- 
cation to the inhibition of dimeric transcription factors, 
such as the basic-helix-loop-helix protein (bHLH) E47. 
E47 plays an essential role in activating expression of the 
immunoglobulin light-chain gene through binding at the 
KEZ enhancer site [ll]. The gene for E47 (EZA) is involved 
in chromosomal translocations that have been found in 
patients with pre-B-cell acute lymphoblastic leukemia [12]. 
E47 was one of the first transcription factors to be classified 
as a bHLH protein [13], and the determination of its 
co-crystal structure with DNA confirmed this prediction 
[14]. The structure of E47 consists of a highly basic region 
that binds into the major groove of DNA in a helical confor- 
mation, and two amphiphilic helices that form the four- 
helix bundle dimerization interface (Figure 1) [14,1.5]. 
The regulation of transcription by the bHLH proteins is 
governed by their ability to form homodimers or het- 
erodimers [16]. Certain members of the HLH family of 
proteins can act as dominant-negative regulators of tran- 
scription, such as the protein Id [17]. The Id protein con- 
tains a HLH domain but lacks the basic region and 
preferentially binds with E47 or El2 proteins to form inac- 
tive complexes, thereby down-regulating bHLH-medi- 
ated transcription [IS]. It was hypothesized that it would 
be possible to disrupt the dimerization of E47, and 
thereby prevent DNA binding, using interfacial peptides 
that correspond to the dimerization domain of E47. Thus, 
peptides corresponding to helix I and helix II (Figure 2) 
were explored as agents to inhibit the dimerization and 
DNA binding of this protein. We have found that these 
interfacial peptides were effective inhibitors of both 
dimerization and DNA binding as hypothesized. Further- 
more, the most potent inhibitor, helix II, displayed 
P-sheet secondary structural features that we have corre- 
lated with its inhibitory potential. 
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Figure 1 Figure 3 
Structure of E47 bound to DNA [14]. Helix I, green; helix II pink; the 
lysine residues available for cross-linking are red. 
Results and discussion 
Inhibition of E47 DNA binding by interfacial peptides 
The inhibition of DNA binding by the interfacial peptides 
was monitored by gel mobility shift assays with E47 (8 PM) 
and an oligonucleotide containing the KEZ enhancer 
sequence (CAGGTG) [13,19] with added amounts of 
peptide (Figure 3). High concentrations of helix I were 
needed to inhibit E47 DNA binding (IC,, of 124 PM; 
Figure 3b). Helix II, on the other hand, was a highly effec- 
tive DNA-binding inhibitor (Figure 3a,b); at equimolar con- 
centrations of helix II and E47 (8 PM) DNA binding was 
abolished (IC,, of 3.7 PM). Peptides corresponding to a 
truncated helix II, 2H10, and single point mutants, 
ZHlOA41 (A41, Ile4+Ala), were also prepared to address 
the specificity of the peptidelprotein interaction. 2HlO was 
less effective at blocking the DNA binding of E47 with an 
IC,, value of 19pM (Figure 3b), whereas 2HlOA41 was 
even less effective with an IC,, value of 47 pM (Figure 3b). 
These data suggest that a specific complex is forming 
between helix II and E47, as truncations of helix II, as in 
the 2HlO peptide, leads to a fivefold decrease in inhibition. 
Also, single point mutations, as in the 2HlOA41 peptide, 
leads to a l&fold decrease in inhibition relative to helix II. 
Figure 2 
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E47 DNA-binding inhibition assay. (a) A typical gel mobility shift assay 
for inhibition of E47 DNA binding with helix II: lane 1, 32P-labeled DNA 
alone (10 nM); lane 2, DNA and E47 (8 PM); lane 3, DNA, E47 (8 uM) 
and helix II (1 FM); lane 4, DNA, E47 (8 PM) and helix II (2 yM); lane 5, 
DNA, E47 (8 pM) and helix II (3 ~.LM); lane 6, DNA, E47 (8 FM) and 
helix II (4 PM); lane 7, DNA, E47 (8 PM) and helix II (5 PM); lane 8, DNA, 
E47 (8 ,uM) and helix II (6 PM); lane 9, DNA, E47 (8 pM) and helix II 
(7 PM); lane 10, DNA, E47 (8 FM) and helix II (8 pM). Buffer: 0.5 mM 
Tris-HCI, 0.1 mM EDTA, 0.1 mM DTT, 10% glycerol, pH 7.0, and 1 pg 
of poly-dldC per experiment. (b) Determination of IC,, values for 
helix I 0, helix II 0, 2HlO W, and 2Hl OA4l A. The data for each curve 
were obtained from the densitometric analysis of the relevant 
autoradiograms for the inhibition of E47 DNA binding, and subsequently 
the linear potion of the sigmoidal curve was used for IC,, determination. 
There is an estimated + 10% error in the IC,, values obtained. 
Probing dimerization inhibition 
The disruption of E47 dimerization by the helix II peptide 
was investigated by size-exclusion chromatography, protein 
/ The sequences of peptides derived from the 
Basic Helix I Loop Helix II helix-loop-helix domain of E47 that have 
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Figure 4 Figure 5 
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Size-exclusion chromatography. A standard molecular weight curve 
was generated using bovine serum albumin 0, carbonic anhydrase n , 
cytochrome C A, and aprotinin LI and apparent molecular weights of 
E47 0, and the complex of E47 and helix II 0 were determined by 
interpolation. 
cross-linking and analytical ultracentrifugation. The dimer 
of E47 eluted from a size-exclusion column as a single peak 
with an apparent molecular weight of 15,300 (Figure 4). 
When a mixture of E47 and helix II was applied to the 
same column, however, a single peak eluted corresponding 
to the molecular weight (MW) of the 1:l complex (9,300, 
calculated 10,023), and no peak corresponding to the 
homodimer of E47 was detected (MW = 14,000). 
E47 was also evaluated for inhibition of dimerization by 
cross-linking with sulfo-EGS (Pierce), and the monomer 
and cross-linked dimer were separated using sodium 
dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE; Figure 5). Adding increasing amounts of 
helix11 to E47 prior to the cross-linking reaction led to a 
decrease in the amount of cross-linked dimer formed, 
although a cross-linked peptide/protein band was not 
observed, presumably because of the lack of proximity 
between the single lysine residue in helix II with the 
three lysine residues in E47 (Figure 1). As a control, a 
lysine-containing peptide was evaluated for inhibition of 
dimeric E47 cross-linking, but no decrease in cross-linked 
protein was observed, even at a fivefold excess of the 
control peptide. These results also serve to indicate that a 
specific complex is formed between E47 and helix II. 
Analytical equilibrium ultracentrifugation experiments 
were also performed to determine the aggregation state of 
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SDS-PAGE of cross-linking experiments with E47 and helix II: lane 1, 
E47 alone (10 PM) and sulfa-EGS; lane 2, E47 (IO PM), helix II 
(10 PM), and sulfa-EGS; lane 3, E47 (10 PM), helix II (20 PM), and 
sulfa-EGS; lane 4, E47 (10 FM). Buffer: 0.5 mM phosphate, 0.1 mM 
EDTA, 0.1 mM DTT, pH 7.0, and 5 mM sulfa-EGS per experiment. 
helix II, and to evaluate any changes in the dimerization of 
E47 in the presence of helix II (see the Supplementary 
material). Initial equilibrium experiments with helix II 
(100 l.tM) established that the P-sheet peptide forms large 
aggregates composed of between 125 and 140 monomer 
units depending on the rotor speeds used (MWs of 293,000 
and 331,000 at 3000 and 4000 rpm, respectively). E47 was 
found to sediment as a dimer at a rotor speed of 42,000 rpm 
(MWcalc’d 13,810, MWtheor 13,978), whereas a 1:l mixture of 
E47 and helix II sedimented with a molecular weight of 
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CD spectra of E47 (50 PM; short dashes), helix I, (50 PM; long dashes), 
and helix II (50 PM; solid line). The buffer was composed of 0.5 pM 
phosphate, 0.1 mM EDTA, 0.1 mM DlT, pH 7.0 at 25°C. 
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Helix II induces a p sheet in E47. (a) Circular 
dichroism spectra of: helix II (50 FM; short 
dashes), E47 (50 PM; solid line), 1:l mixture of 
E47 and helix II (50 pM each; long dashes). 
(b) E47 (50 PM; solid line), and difference 
spectrum of the mixture minus helix II (50 PM; 
short dashes). (c) Circular dichroism spectra of 
helix II (75 pM; short dashes), E47 (50 pM; 
solid line), and a 1 :1.5 mixture of E47 (50 FM) 
and helix II (75 PM; long dashes). (d) E47 
(50 FM; solid line) difference spectrum of the 
mixture minus helix II (75 PM; dashes). The 
buffer was composed of 0.5 PM phosphate, 
0.1 mM EDTA, 0.1 mM DlT, pH 7.0 at 25°C. 
The rationale behind the difference spectra is 
explained in the Materials and methods section. 
detectable at high rotor speeds). The molecular weight 
obtained for E47 with equimolar amounts of helix II is 
somewhat higher than what one would anticipate for a 
monomer of E47 (MW 6989), and slightly lower than the 
anticipated molecular weight of a 1:l complex between 
E47 and helix II (MW 9320). Although these results do not 
unequivocally support the possible formation of a 1:l 
complex between E47 and helix II, they do leave open the 
possibility that such a complex exists, as indicated by size- 
exclusion chromatography and DNA-binding experiments. 
These data do support the role of helix II in disrupting the 
dimerization of E47 at equimolar concentrations. 
Secondary structural evaluation of interfacial peptides 
Circular dichroism (CD) was performed to investigate the 
structural basis of inhibition by the helix I and helix II 
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peptides. The CD spectrum of E47 contained two minima 
at 208 and 2’22 nm (Figure 6) as is observed for helical pro- 
teins [ZO]. Surprisingly, the CD spectrum of helix II corre- 
sponded to the spectrum that one would obtain from a 
P-sheet-containing protein (Figure 6), in that a single 
minimum was observed at ‘218 nm, whereas helix I dis- 
played CD spectra characteristic of a random coil [ZO]. 
In order to examine any change in the secondary strut- 
ture of E47 in the presence of helix II (the most potent 
inhibitor), CD spectra were acquired for a mixture of 
helix II (50 mM) and E47 (50 mM; Figure 7a) and also 
helix II (75 mM) and E47 (50 mM) (Figure 7~). The 
spectra of the complexes (E47-helix II) displayed a sig- 
nificantly larger peak at 218 nm than that obtained for 
E47 alone (Figure 7a,c). The change in the secondary 
structure of E47 was evidenced by subtracting the spectra 
of the 50 mM and 75 mM solution of helix II from the 
spectra of their respective complexes (Figure 7b,d). The 
difference spectra of E47 thus obtained showed a signifi- 
cant shift of the minima from 222 nm (indicative of 
a helix) to 218 nm (indicative of p sheet), especially with 
an 1.5 times excess of added helix II (Figure 7d). This 
structural transition in E47 may imply that helix II is 
inducing a P-sheet character in E47. 
Chou-Fasman secondary structural predictions [Zl] indi- 
cated that the first 16 residues in the carboxy-terminal 
helix of E47, KLLILQQAVQVILGLE (using single- 
letter amino acid code), have the potential to adopt 
P-sheet structure. Thus the secondary structure of the 
peptides ZHlO, and 2HlOA41 were also investigated using 
CD spectroscopy (Figure 8). It was shown that the 
peptide 2HlO was capable of adopting a P-sheet structure, 
whereas 2HlOA41 adopted a random-coil structure. This is 
perhaps not surprising, given the importance of p- 
branched isoleucine residues in promoting P-sheet sec- 
ondary structure, in both statistical [ZZ] and experimental 
studies [23,24]. It is remarkable, however, that a single 
residue Ile4-+Ala mutation, not only abolishes the P-sheet 
structure but substantially diminishes the inhibitory 
potential (Figure 3b). This adds further credence to the 
importance of the P-sheet structure in modulating the 
inhibitory properties of these peptides. 
The results from CD spectroscopy provide a possible 
mechanism of inhibition for E47-DNA complexation. In 
this mechanism, helix II, a peptide that exists in a helical 
conformation when in the protein framework of E47, 
adopts a P-sheet structure in solution and induces a corre- 
sponding structural change in E47, thereby abrogating 
DNA binding. Furthermore, evidence from size-exclusion 
chromatography, cross-linking and analytical ultracentrifu- 
gation studies support the role of the 20 amino acid 
peptide helix II in inhibiting the dimerization and DNA 
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CD spectra of 2HlO (50 PM; solid line) and 2Hl OA41 (50 PM; dashed 
line). The buffer was composed of 0.5 mM phosphate, 0.1 mM EDTA, 
0.1 mM DTT, pH 7.0 at 25°C. 
P-sheet structure in a helical protein is not unprecedented 
[25]; the progression of the prion disease state is believed 
to occur by such a mechanism [26]. Cohen and coworkers 
[27,‘28] have shown that a prion-derived peptide was able 
to induce P-sheet structure in other prion-derived peptides 
that have random-coil or a-helical secondary structures. 
Furthermore, recent work by Minor and Kim [29] and 
Regan and coworkers [30] has delineated the importance 
of tertiary interactions as determinants for secondary struc- 
ture. Thus helix II provides a new example of an inher- 
ently P-sheet forming sequence that can exist as an a helix 
in the protein framework of E47. 
The use of interfacial peptides for the inhibition of 
oligomeric enzymes as well as receptor-protein-mediated 
signaling has received considerable attention recently [lo]. 
The application of this protein-protein disruption strategy 
has not been extended to the realm of dimeric transcrip- 
tion factors, however. Thus, the development and imple- 
mentation of peptide-based dimerization inhibitors in this 
study might prove to be of considerable use in the direct 
and specific targeting of transcription factors that are 
implicated in abnormal cellular proliferation. 
Significance 
The inhibition of transcription factors is a potential tber- 
apeutic strategy and requires the design of suitable 
inhibitory agents. This study demonstrates the inhibition 
of the basic helix-loop-helix (bHLH) transcription factor 
E47 using peptides corresponding to its dimerization 
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interface. The identification of helix II, a P-sheet-forming 
peptide that abrogates E47 dimerization and DNA 
binding at equimolar concentrations, underscores the 
potential for the dimerization inhibition strategy. More- 
over, the induction of P-sheet structure upon the predom- 
inantly a-helical E47 protein by helix II highlights the 
structural plasticity of the E47 tertiary structure. This 
study therefore not only provides a rational framework 
for the design of dimerization inhibitors, but also opens 
the door for the conformational analysis of peptides 
derived from the bHLH family of transcription factors, 
which might help delineate the factors that govern the 
secondary and tertiary structures of this class of proteins. 
Materials and methods 
Synthesis of peptides 
The peptides: helix II helix II1 2H10, and 2Hl OA41, were synthesized 
using solid phase methodology on a Rink amide resin [31 I using a fluo- 
renylmethyloxy-carbonyl (Fmoc)-based strategy [32] on a Biosearch 
9500 peptide synthesizer. The synthesis and characterization of E47 
together with the general synthesis and cleavage procedures for resin- 
bound peptides have been previously described [l 91. All peptides were 
purified to homogeneity using high-performance liquid chromatography 
(HPLC) on a Vydac C8 reverse phase semi-preparative column, 
2.2 x 25 cm, 8.0 ml/min, mobile phase A (100% CHsCN, 0.1% TFA) 
and mobile phase B (100% H,O, 0.1% TFA). Peptides were purified 
with linear gradients (1 O-50% for helix I; 15-550/o for helix II; 1 O-65% 
for 2HlO and 2Hl OA4l) over 60 min on a Waters Delta Prep 4000. 
The eluant was monitored at 214 nm. The peptides were judged to be 
greater than 95% pure by analytical reverse-phase HPLC. The peptides 
were characterized by plasma-desorption mass spectrometry, and 
amino-acid analysis (see the Supplementary material). 
Electrophoretic mobility shift assays 
EMSAs were performed with 32P-labeled 29 base pair double stranded 
oligonucleotide probe containing a CAGGTG DNA-binding sequence 
[33]. The 5’ sense strand of the DNA probe is as follows: 
5’-AATTCGCGGCCGCAGAACAGGTGGTCCAG-3’. The DNA was 
radiolabeled using the Klenow fragment of DNA Polymerase (New 
England Biolabs) in the presence of dCTP, dGTP, dTTP and 5’-w3*P- 
dATP (Amersham) and purified through a Nick column (Pharmacia- 
Biotech) containing Sephadex G-25. Typical inhibition assays involved 
the incubation of E47 (10 mM) with or without a given concentration of 
the peptide inhibitor for 1 hour in Buffer A (0.5 mM phosphate, 0.1 mM 
EDTA, 0.1 mM Dll’, at pH 7.0). This was followed by the addition of 
10 nM labeled DNA probe, 100/o glycerol and 1 mg poly-dldC and further 
incubation for 30 min in a total volume of 20 ul at room temperature. The 
reactions were analyzed by 8% nondenaturing PAGE. Densitometric 
analysis of the relevant autoradiograms allowed the measurement of the 
relative intensities of the protein/DNA bands. Sigmoidal curves were 
obtained by plotting the decrease in intensity of the protein/DNA band as 
a function of inhibitor concentration. The IC,, values were determined by 
a least squares analysis of the linear portion of the sigmoidal curves. 
Size-exclusion chromatography 
A solution of E47 (250 pl, 200 KM) and helix II (250 ul, 800 mM) was 
run through Sephadex G-50 (90 x 1.6 cm column) with a flow rate of 
0.3 mllmin at 4°C and a buffer composed of 10 mM phosphate, 
50 mM NaCI, buffer at pH 7.0. The eluant was monitored at 214 nm. A 
standard molecular weight curve was generated using bovine serum 
albumin, carbonic anhydrase, cytochrome C, and aprotinin, and appar- 
ent molecular weights were determined by interpolation. 
Cross-linking experiments 
Cross-linking experiments were performed at room temperature in Buffer 
A with a 500-fold excess of an amine-reactive cross-linking reagent, 
sulfa-EGS (Pierce). E47 was incubated in the presence or absence of an 
appropriate concentration of helix II for 2 h, upon which the reaction was 
stopped by the addition of gel-loading buffer and subsequent heating to 
100°C. The reactions were analyzed immediately by 17% SDS-PAGE 
and the resulting protein bands were visualized by silver staining. A 
control cross-linking experiment was also performed with E47 in the 
presence of a peptide containing six lysine residues, EELEKKLKELEEK- 
LKK-NH, [341. The concentrations of E47, helix II, and the control 
peptide were verified by amino-acid analysis. 
Analytical ultracentrifugation 
Analytical equilibrium ultracentrifugation was carried out on a Beckman 
XLA analytical ultracentrifuge (Purdue Cancer Center) at 25°C with 
peptide samples in 0.5 mM phosphate buffer at pH 7.0. The partial 
specific volumes were calculated on the basis of the amino acid com- 
position. Equilibrium data were collected over a period of 48 h in all 
cases and equilibrium was judged complete when successive scans 
were superimposable. The absorbance was monitored at 214 nm for 
helixll, and 230 nm for E47 and the 1 :l mixture of E47 and helix II. The 
data were subjected to global analysis with the program SEDEQ and fit 
to a single molecular weightspecies for ease of interpretation 1351. 
Circular dichroism spectroscopy 
CD spectra were recorded on a Jasco J600 spectropolarimeter at 
24’C in Buffer A using a 0.2 cm path length cell. CD spectra for E47, 
helix I, helix II, 2H10, 2Hl OA4l were recorded at 50 uM concentrations. 
For experiments to determine the change in secondary structure of E47 
in the presence of helix II, E47 was incubated for 120 min with or 
without helix II for 1 h in Buffer A at room temperature. Subsequently, 
the CD spectra of (i) helix II (50 PM), (ii) E47 (50 PM), (iii) E47 (50 FM) 
and helix II (50 FM) were recorded as an average of four scans from 
260 to 200 nm with a resolution of 0.2 nm and a scan rate of 
10 nm/min (Figure 7a). The spectra of the E47 alone, (ii), was sub- 
tracted from the spectra of E47 and helix II, (iii), to give a spectra of 
E47 in the presence of helix II (Figure 7b). The spectra for E47 in the 
presence of 75 uM helix II was treated similarly (Figure 7c,d). The con- 
centration of E47 and helix II was determined from amino-acid analysis. 
The assumption was made that the secondary structure of helix II is not 
prone to change as was evidenced by thermal and Urea denaturation 
experiments (see the Supplementary material). 
Supplementary material available 
Characterization of the peptides used in this study, analytical ultracen- 
trifugation data and thermal and urea denaturation studies with helix II 
using circular dichroism are available upon request and on the internet. 
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